The global D-dimer testing market size is expected to reach USD 1.7 billion by 2027, expanding at a CAGR of 4.3%, according to a new report by Grand View Research, Inc. Technological advancements in D-dimer testing have resulted in the development of a wide range of products that have allowed healthcare professionals to offer suitable emergency assistance to patients. The concept of automation in D-dimer testing has provided rapid, less labor-intensive, and user-friendly diagnostic strategies, which is expected to drive the market in the near future.
The
commercially available assays often have differences in their antibody
specificity as D-dimer antibodies also detect Fibrin Degradation Products
(FDPs), leading to incorrect results. To address this issue, Advanced
ImmunoChemical, Inc. has developed two monoclonal antibodies, which are
used to design one-step immunoassay specific for both FDP and D-dimer. Thus,
the development of improved immunoassays that equally detect all FDPs is
expected to boost the market growth.
Extensive
research for the determination of new D-dimer threshold values for a specific
population set prevents the usage of Computed Tomography Pulmonary Angiography
(CTPA). This is beneficial as the elimination of CTPA leads to low radiation
exposure, which, in turn, increases the demand for the test. To demonstrate
this, a group of researchers from Japan determined new elevated D-dimer
threshold values for the diagnosis of pulmonary embolism in the Japanese
population. Such studies are expected to favor market growth.
Full Research Report On D-dimer Testing Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/d-dimer-market
D-dimer Testing
Market Report Highlights
- Reagents and
consumables accounted for the largest revenue share in 2019 owing to the
wide availability and frequent usage of reagents in the market space
- Presence of
blocking agents that reduce the interferences from heterophilic antibodies
to increase the efficiency of immunoassays boost the reagents and
consumables segment
- Shorter
turnaround times, ease of use, and generation of gold-standard quality results
are among the few factors that lead to a lucrative growth of point-of-care
testing
- Enzyme-linked
Immunosorbent Assays (ELISA) held the largest revenue share because
microplate ELISA is considered as a reference method due to its high
sensitivity for coagulation markers
- Deep Vein
Thrombosis (DVT) dominated the revenue share in 2019 as this test is a
reliable method and is used as a routine screening test for DVT
- The
hospitals' segment accounted for the maximum revenue share in 2019
- This is
attributive to a rise in the rate of pulmonary embolism cases in
hospitalized patients, which results in high adoption of the test in
hospitals
- Asia Pacific
is expected to witness a lucrative CAGR due to a rise in the funding
initiatives that support research studies related to the usage of these
assays in various diseases
- The National
Natural Science Foundation of China and the Fundamental Research Funds for
the Central Universities are among the few agencies involved in funding
research studies in China
- Key companies
operating in the market have undertaken several growth initiatives to
expand their product portfolio
- For instance,
in February 2019, HORIBA introduced the Yumizen D-Dimer reagent kit for
measurement and reference exclusion testing for DVT and pulmonary
embolism.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/d-dimer-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company, registered
in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment